Thrombosis Research
Volume 121, Issue 2 , Pages 145-151, 2007

Venous thromboembolism in carriers of the Factor V Leiden mutation and in patients without known thrombophilic risk factor; prediction of recurrence and APC–PCI complex concentration and/or soluble thrombomodulin antigen and activity

  • Karin Strandberg

      Affiliations

    • Department of Clinical Chemistry, Lund University, Malmö University Hospital, SE-205 02 Malmö, Sweden
    • Corresponding Author InformationCorresponding author. Tel.: +46 40 33 1459; fax: +46 40 336286.
  • ,
  • Peter J. Svensson

      Affiliations

    • Department of Coagulation Disorders, Lund University, Malmö University Hospital, Sweden
  • ,
  • Ann-Kristin Öhlin

      Affiliations

    • Department of Clinical Chemistry, Lund University, Lund University Hospital, Sweden

Received 19 November 2006; received in revised form 19 February 2007; accepted 27 March 2007.

Abstract 

Background

The complex between activated protein C (APC) and the protein C inhibitor (PCI) is a sensitive indicator of the degree of activation of blood coagulation and higher concentrations have been measured in carriers of the FV Leiden mutation who were in the recovery phase after treatment for venous thromboembolism (VTE).

Objectives

The main purpose of this study was to correlate the APC–PCI complex concentration to thrombomodulin activity and antigen concentration in the same group of patients. We also add a prospective clinical follow-up of the VTE recurrence after 1 year to investigate if the markers can predict the risk for a new VTE.

Patients/Methods

Blood samples were collected from 50 patients with the FV Leiden mutation and 132 without any known risk factor for thrombophilia after finished treatment.

Results

The APC–PCI complex, s-TM activity and the quotient (s-TM activity)/(s-TM antigen) were higher in VTE patients with FV Leiden. In total, there were 19 VTE recurrences (10%) after 1 year. The OR for recurrence was 1.9 (95% CI 0.68–5.0) in all VTE patients with elevated APC–PCI complex (above 75th percentile) and 3.6 (95% CI 1.1–12) in VTE patients without any known risk factor for thrombophilia and with elevated s-TM activity.

Conclusion

The APC–PCI complex concentration, s-TM activity and the quotient (s-TM activity)/(s-TM antigen) were higher in VTE patients with FV Leiden. The s-TM activity showed higher OR for recurrence of VTE in patients without known thrombophilic risk factor. Both methods could be sensitive markers of increased risk for venous thrombosis.

Abbreviations:: APC, activated protein C, PCI, protein C inhibitor, VTE, venous thromboembolism, s-TM, soluble thrombomodulin, DVT, deep vein thrombosis, FV, Factor V.

Keywords: APC–PCI complex concentration, s-TM activity, s-TM antigen, VTE patients, FV Leiden, VTE recurrence

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

PII: S0049-3848(07)00122-3

doi:10.1016/j.thromres.2007.03.020

Thrombosis Research
Volume 121, Issue 2 , Pages 145-151, 2007